Benzodiazepine Use and Misuse Among Adults in the United States
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Goals were to determine the prevalence of benzodiazepine use (as prescribed and misuse), characterize misuse, and examine variation by age. METHODS: A cross-sectional analysis was conducted of 2015 and 2016 National Survey on Drug Use and Health data limited to adults ≥18 (N=86,186) and data from those respondents reporting benzodiazepine use (N=10,290). Measurements included past-year prescription benzodiazepine use and misuse ("any way a doctor did not direct"), substance use disorders, mental illness, and demographic characteristics. Misuse was compared between younger (18-49) and older (≥50) adults. RESULTS: A total of 30.6 million adults (12.6%) reported past-year benzodiazepine use-25.3 million (10.4%) as prescribed and 5.3 million (2.2%) misuse. Misuse accounted for 17.2% of overall use. Adults ages 50-64 had the highest prescribed use (12.9%). Those ages 18-25 had the highest misuse (5.2%), and those ages ≥65 had the lowest (.6%). Misuse and abuse of or dependence on prescription opioids or stimulants were strongly associated with benzodiazepine misuse. Benzodiazepine misuse without a prescription was the most common type of misuse, and a friend or relative was the most common source. Adults ages ≥50 were more likely than younger adults to use a benzodiazepine more often than prescribed and to use a benzodiazepine to help with sleep. CONCLUSIONS: Benzodiazepine use among U.S. adults was higher than previously reported, and misuse accounted for nearly 20% of use overall. Use by adults ages 50-64 now exceeds use by those ages ≥65. Patients also prescribed stimulants or opioids should be monitored for benzodiazepine misuse. Improved access to behavioral interventions for sleep or anxiety may reduce some misuse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Since benzodiazepines are among the most frequently prescribed drugs in the United States, treatments for BIND represent an urgent unmet medical need [25].”
From Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey (2023) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13702 · Cited by 2,609
The American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03923.x · Cited by 2,578
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2016) · Annals of Internal Medicine · doi:10.7326/m15-2175 · Cited by 1,965 · cited 1×
“A significant proportion of the NSDUH-defined “misuse”, therefore, could reflect use for untreated symptoms among those with poor access to care—specifically behavioral treatments for insomnia (31, 32) or anxiety disorders (33, 34).”
BackgroundMeta-analysis of the Impact of 9 Medication Classes on Falls in Elderly Persons
Woolcott, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.357 · Cited by 1,326 · cited 1×
“While use among those ≥65 has not been declining (1, 3), the decades of evidence regarding safety concerns (4, 7, 27) and professional guidelines (6, 28) recommending limited use in older adults may have helped slow growth.”
BackgroundExplicit Criteria for Determining Potentially Inappropriate Medication Use by the Elderly: An Update
Beers, M. H. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440350031003 · Cited by 1,059 · cited 1×
“While use among those ≥65 has not been declining (1, 3), the decades of evidence regarding safety concerns (4, 7, 27) and professional guidelines (6, 28) recommending limited use in older adults may have helped slow growth.”
BackgroundBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676 · cited 1×
“A significant proportion of the NSDUH-defined “misuse”, therefore, could reflect use for untreated symptoms among those with poor access to care—specifically behavioral treatments for insomnia (31, 32) or anxiety disorders (33, 34).”
BackgroundPark, T. W., Saitz, R., Ganoczy, D., Ilgen, M. A., & Bohnert, A. S. B. (2015) · BMJ · doi:10.1136/bmj.h2698 · Cited by 579
Help-seeking behaviour in men and women with common mental health problems: cross-sectional study
Oliver, M. I., Pearson, N., Coe, N., & Gunnell, D. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.186.4.297 · Cited by 558 · cited 1×
“This may further support the hypothesis that higher misuse is partially a function of limited access to a prescribed option—limited for younger patients due to lack of insurance and for men due to minimal disclosure of mental health concerns to providers (42).”
BackgroundBenzodiazepines of Long and Short Elimination Half-life and the Risk of Hip Fracture
Ray, W. A. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430230088031 · Cited by 548 · cited 1×
“While use among those ≥65 has not been declining (1, 3), the decades of evidence regarding safety concerns (4, 7, 27) and professional guidelines (6, 28) recommending limited use in older adults may have helped slow growth.”
Background
Research works printed but not linked: 2
- Lipari RN, Williams M, Van Horn SL. Why Do Adults Misuse Prescription Drugs? 2017 7 27 In: The Center for Behavioral Health Statistics and Quality Report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US) Available from: https://www.ncbi.nlm.nih.gov/books/NBK458284/ 28968046
- Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey on Drug Use and Health: Summary of the Effects of the 2015 NSDUH Questionnaire Redesign: Implications for Data Users. Substance Abuse and Mental Health Services Administration, Rockville, MD. 30199192
Cited by
The epidemiology of benzodiazepine misuse: A systematic review*
Votaw, V. R., Geyer, R., Rieselbach, M. M., & McHugh, R. K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.033 · Cited by 479
Wilson, S., Anderson, K., Baldwin, D., Dijk, D.-J., Espie, A., Espie, C., Gringras, P., Krystal, A., Nutt, D., Selsick, H., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855343 · Cited by 312
“Despite the recommendation for treatment with hypnotic drugs being only 2–4 weeks, many millions of patients worldwide remain on long-term treatment (Ohayon et al., 1999; Maust et al., 2019).”
BackgroundBalancing the Risks and Benefits of Benzodiazepines
Hirschtritt, M. E., Olfson, M., & Kroenke, K. (2021) · JAMA · doi:10.1001/jama.2020.22106 · Cited by 96
Ngcobo, N. N. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01466-0 · Cited by 199
“Maust et al. observed that benzodiazepine usage increased with age among members of a large health maintenance organisation in the USA [97].”
Xu, K. Y., Hartz, S. M., Borodovsky, J. T., Bierut, L. J., & Grucza, R. A. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.28557 · Cited by 94
GABAA receptor subtypes and benzodiazepine use, misuse, and abuse
Engin, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1060949 · Cited by 95
“More alarmingly, while the number of new BDZ prescriptions remained stable between 2005 and 2015, there was a 50% increase in renewed prescriptions during the same period, suggesting a specific increase in this problematic, longer-term use (54).”
BackgroundBenzodiazepines and Related Sedatives
Peng, L., Morford, K. L., & Levander, X. A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.012 · Cited by 86
Benzodiazepine Misuse: An Epidemic Within a Pandemic
Sarangi, A., McMahon, T. C., & Gude, J. G. (2021) · Cureus · doi:10.7759/cureus.15816 · Cited by 144
“6%) reported benzodiazepine use in the year 2015-2016 [23].”
BackgroundPrescription Drug Misuse: Taking a Lifespan Perspective
Schepis, T. S., Klare, D. L., Ford, J. A., & McCabe, S. E. (2020) · Substance Abuse Research and Treatment · doi:10.1177/1178221820909352 · Cited by 77
Winer, J. M., Yule, A. M., Hadland, S. E., & Bagley, S. M. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2104922 · Cited by 58
“report prior benzodiazepine exposure [86,87].”
Alabaku, O., Yang, A., Tharmarajah, S., Suda, K. J., Vigod, S. N., & Tadrous, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284389 · Cited by 74
Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects
Edinoff, A. N., Nix, C. A., Odisho, A. S., Babin, C. P., Derouen, A. G., Lutfallah, S. C., Cornett, E. M., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022) · Neurology International · doi:10.3390/neurolint14030053 · Cited by 74
“It was found that the percentage of benzodiazepine users increases with age, and its use was nearly twice as prevalent in women compared with men [8].”
BackgroundInfluentialEvrard, P., Pétein, C., Beuscart, J.-B., & Spinewine, A. (2022) · Implementation Science · doi:10.1186/s13012-022-01206-7 · Cited by 62
Liu, L., Jia, L., Jian, P., Zhou, Y., Zhou, J. H., Wu, F., & Tang, Y. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00755 · Cited by 73
“The data extraction form contained the following information: (1) author and publication year, (2) study design, (3) setting (country), (4) study design, (5) mean age, (6) gender distribution, (7) education, (8) participants sources, (9) details of BZD use (BZD types, using time, dosage, and the definition of BZD use)…”
BackgroundMethodAnesthetic Considerations for Patients on Psychotropic Drug Therapies
Harbell, M. W., Dumitrascu, C., Bettini, L. M., Yu, S., Thiele, C. M., & Koyyalamudi, V. (2021) · Neurology International · doi:10.3390/neurolint13040062 · Cited by 64
Targeting Sleep Physiology to Modulate Glymphatic Brain Clearance
van Hattem, T., Verkaar, L., Krugliakova, E., Adelhöfer, N., Zeising, M., Drinkenburg, W. H. I. M., Claassen, J. A. H. R., Bódizs, R., Dresler, M., & Rosenblum, Y. (2024) · Physiology · doi:10.1152/physiol.00019.2024 · Cited by 75
Benzodiazepines: it's time to return to the evidence
Silberman, E., Balon, R., Starcevic, V., Shader, R., Cosci, F., Fava, G. A., Nardi, A. E., Salzman, C., & Sonino, N. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2020.164 · Cited by 54
Drug checking identifies counterfeit alprazolam tablets
Tobias, S., Shapiro, A. M., Grant, C. J., Patel, P., Lysyshyn, M., & Ti, L. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108300 · Cited by 49
Polypharmacy in patients with epilepsy: A nationally representative cross-sectional study
Terman, S. W., Aubert, C. E., Hill, C. E., Maust, D. T., Betjemann, J. P., Boyd, C. M., & Burke, J. F. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.107261 · Cited by 51
“Approximately 5–10% of US adults are prescribed a benzodiazepine [32,33].”
BackgroundSelf-citationMaust, D. T., Petzold, K., Strominger, J., Kim, H. M., & Bohnert, A. S. B. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.48557 · Cited by 47
Self-citationChang, Y., Xie, X., Liu, Y., Liu, M., & Zhang, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116329 · Cited by 44
Limited Utility for Benzodiazepines in Chronic Pain Management: A Narrative Review
Wright, S. L. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01354-6 · Cited by 44
Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey
Ritvo, A. D., Foster, D. E., Huff, C., Finlayson, A. J. R., Silvernail, B., & Martin, P. R. (2023) · PLOS ONE · doi:10.1371/journal.pone.0285584 · Cited by 38
“among the most frequently prescribed drugs in the United States, treatments for BIND represent an urgent unmet medical need [25].”
BackgroundBarbaux, L., Perrault, A. A., Cross, N. E., Weiner, O. M., Essounni, M., Pomares, F. B., Tarelli, L., McCarthy, M., Maltezos, A., Smith, D., et al. (2025) · SLEEP · doi:10.1093/sleep/zsaf168 · Cited by 34
A hidden confounder for microbiome studies: medications used years before sample collection
Aasmets, O., Taba, N., Krigul, K. L., Andreson, R., Estonian Biobank Research Team, Org, E., Metspalu, M., Metspalu, A., Milani, L., & Esko, T. (2025) · mSystems · doi:10.1128/msystems.00541-25 · Cited by 30
Babiloni, A. H., Beetz, G., Bruneau, A., Martel, M. O., Cistulli, P. A., Nixdorf, D. R., Conway, J. M., & Lavigne, G. J. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101459 · Cited by 33
Benzodiazepines in complex biological matrices: Recent updates on pretreatment and detection methods
Zhang, Y.-X., Zhang, Y., Bian, Y., Liu, Y., Ai, R., Zhou, Y., Shi, D., & Feng, X. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.03.007 · Cited by 30
“use of BDZs by adults in the United States and the number of deaths caused by illegal use of BDZs were higher than previously reported, and misuse accounted for about 20% of total usage [17].”
BackgroundPharmacokinetic and pharmacodynamic alterations in older people: what we know so far
Mangoni, A. A., Woodman, R. J., & Jarmuzewska, E. A. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2503848 · Cited by 33
Prescription Benzodiazepine Use in Privately Insured U.S. Children and Adolescents
Bushnell, G., Crystal, S., & Olfson, M. (2019) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2019.07.006 · Cited by 29
de Dios, C., Fernandes, B. S., Whalen, K., Bandewar, S., Suchting, R., Weaver, M. F., & Selvaraj, S. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109176 · Cited by 28
“%) reporting benzodiazepine use in the past year (Maust et al., 2019).”
Use of Benzodiazepines and Risk of Incident Dementia: A Retrospective Cohort Study
Gerlach, L. B., Kim, H. M., Ignacio, R. V., Strominger, J., & Maust, D. T. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab241 · Cited by 33
Self-citationAssociation of New Perioperative Benzodiazepine Use With Persistent Benzodiazepine Use
Wright, J. D., Cogan, J. C., Huang, Y., Tergas, A. I., Clair, C. M. S., Hou, J. Y., Khoury‐Collado, F., Gockley, A. A., Accordino, M. K., Melamed, A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.12478 · Cited by 29
“0) 10 (3-30) 320 (11) Appendectomy 1784 (2.”
Benzodiazepine Use among Medicare, Commercially Insured , and Veteran Older Adults, 2013–2017
Maust, D. T., Kim, H. M., Wiechers, I. R., Ignacio, R. V., Bohnert, A. M., & Blow, F. C. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16825 · Cited by 27
“We used a lower age cutoff of 55 rather than 65 years given evidence of growing BZD use among middle-aged adults,(10) with use that now equals or exceeds that of adults aged 65 and older in the general population.(19) Second, to account for the potential that different prescribing patterns might reflect differences in…”
MethodSelf-citationCooper, R. E., Ashman, M., Lomani, J., Moncrieff, J., Guy, A., Davies, J., Morant, N., & Horowitz, M. (2023) · PLOS ONE · doi:10.1371/journal.pone.0282988 · Cited by 23
“4% of people are using benzodiazepines [5] and benzodiazepinerelated deaths have risen [6], which has generated concern.”
BackgroundPatterns of Polysubstance Use among Adults with Tranquilizer Misuse
Votaw, V. R., McHugh, R. K., Vowles, K. E., & Witkiewitz, K. A. (2020) · Substance Use & Misuse · doi:10.1080/10826084.2019.1708118 · Cited by 23
Sociodemographic Differences in Quality of Treatment to Medicaid Enrollees Receiving Buprenorphine
Landis, R. K., Levin, J. S., Saloner, B. K., Gordon, A. J., Dick, A. W., Sherry, T. B., LESLIE, D. L., Sorbero, M., & Stein, B. D. (2022) · Substance Abuse · doi:10.1080/08897077.2022.2060424 · Cited by 23
Luo, H., Chai, Y., Li, S., Lau, W. C. Y., Torre, C. O., Hayes, J., Lam, I. C. H., Lin, X., Yin, C., Fortin, S., et al. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00245-1 · Cited by 24
“40 Although continuously elevated prescribing rates were observed in one to two databases for antidepressants and antipsychotics only, the increase in antipsychotic rates among people with anxiety disorders in the UK and South Korea (KNU) was considerable, with the highest rate ratios observed…”
Trajectories of Prescription Drug Misuse Among US Adults From Ages 18 to 50 Years
McCabe, S. E., Schulenberg, J. E., Schepis, T. S., Evans‐Polce, R. J., Wilens, T. E., McCabe, V. V., & Veliz, P. T. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.41995 · Cited by 21
Benzodiazepines: Thinking outside the black box
Pergolizzi, J. V., LeQuang, J. A., & Raffa, R. B. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13333 · Cited by 20
Benzodiazepine use disorder: A cross-sectional study at a tertiary care center in Lebanon
Zahran, T. E., Kanaan, E., Kobeissi, L., Bouassi, J., Sarieddine, A., Carpenter, J. E., Kazzi, Z., & Hitti, E. A. (2022) · Medicine · doi:10.1097/md.0000000000030762 · Cited by 21
“In addition to the pattern of increased prescribing of benzodiazepines by physicians, Lembke et al [7] showed that patients are not aware of the addiction potential is another factor.”
Maust, D. T., Bohnert, A. S. B., Strominger, J., Alexander, N. B., Min, L. C., Hoffman, G. J., & Goldstick, J. E. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03497-3 · Cited by 22
Self-citationMcCarthy, B., O’Neill, G. J., & Abu‐Ghannam, N. (2022) · Marine Drugs · doi:10.3390/md20080493 · Cited by 22
Peri, S., Neppala, G. K., Shaik, R., & Parvaz, M. A. (2024) · Current Addiction Reports · doi:10.1007/s40429-024-00582-y · Cited by 24
Benzodiazepine Use and Dependence in Relation to Chronic Pain Intensity and Pain Catastrophizing
Lape, E. C., Powers, J. M., Hooker, J. E., Edwards, R. R., & Ditre, J. W. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.09.019 · Cited by 22
“Variables that were associated with dependent variables (past-month BZD use frequency, BZD dependence, BZD misuse) were retained as covariates in addition to covariates selected a priori (age, sex; Cunningham et al., 2017b; Maust et al., 2019; Olfson et al., 2015).”
BackgroundMethodHernández‐Esteve, I., Zumbado, M. L., & Henríquez‐Hernández, L. A. (2024) · Veterinary Record · doi:10.1002/vetr.4960 · Cited by 24
Ostroumov, A., Wittenberg, R. E., Kimmey, B. A., Taormina, M. B., Holden, W. M., McHugh, A. T., & Dani, J. A. (2020) · eNeuro · doi:10.1523/eneuro.0348-19.2020 · Cited by 24
“Among the different classes of GABAAR-targeting drugs, benzodiazepine misuse is a growing public health problem in the United States, with prescription rates and overdose mortality spiking in recent years (Bachhuber et al., 2016; Lembke et al., 2018; Maust et al., 2019).”
BackgroundBushnell, G., Olfson, M., & Martins, S. S. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108609 · Cited by 21
Epidemiologic assessment of benzodiazepine exposure among suicide deaths in Colorado, 2015–2017
Ghosh, T., Bol, K., Butler, M., Gabella, B., Kingcade, A., Kaplan, G., & Myers, L. (2020) · BMC Public Health · doi:10.1186/s12889-020-09250-y · Cited by 17
Patient Perceptions of Opioids and Benzodiazepines and Attitudes Toward Deprescribing
Kelley, C. J., Niznik, J. D., Ferreri, S. P., Schlusser, C. L., Armistead, L. T., Hughes, T. D., Henage, C. B., Busby‐Whitehead, J., & Roberts, E. (2023) · Drugs & Aging · doi:10.1007/s40266-023-01071-z · Cited by 17
“However, the demographic breakdown (race and sex) did reflect the demographics of the patients in the study clinics who were taking opioids and BZDs and the fact that White female individuals are prescribed opioids and BZDs more frequently [39–41].”
BackgroundGan, T., Jackson, N. A., Castle, J. T., Davenport, D. L., Oyler, D. R., Ebbitt, L. M., Evers, B. M., & Bhakta, A. S. (2020) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001655 · Cited by 17
“Over the same period, sedative use increased by 50%, particularly in patients between 50 and 64 years of age, which led to increased falls and fractures.(4) In addition, sedatives such as benzodiazepines are commonly prescribed along with opioids, leading to an even higher risk of overdose and death.”
BackgroundBenzodiazepine Use Among Older Adults
Gupta, A., Bhattacharya, G., Balaram, K., Tampi, D. J., & Tampi, R. R. (2020) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0056 · Cited by 20
Navarrete, F., Marín, M., Martínez-Hostyn, L., Rubio, G., & Manzanares, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031430 · Cited by 19
Bipolar Disorder and Polysubstance Use Disorder: Sociodemographic and Clinical Correlates
Aguglia, A., Natale, A., Fusar‐Poli, L., Amerio, A., Bruno, E., Placenti, V., Vai, E., Costanza, A., Serafini, G., Aguglia, E., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.913965 · Cited by 18
Altuwairqi, Y. A. (2024) · Cureus · doi:10.7759/cureus.55452 · Cited by 24
“Another class of drugs examined in the included studies was anxiolytics, which are prescribed for the treatment of panic disorders, generalized anxiety, and other related conditions [41,42].”
BackgroundBenzodiazepine Treatment and Fracture Risk in Young Persons With Anxiety Disorders
Bushnell, G., Gerhard, T., Crystal, S., & Olfson, M. (2020) · PEDIATRICS · doi:10.1542/peds.2019-3478 · Cited by 18
Ionic Plasticity: Common Mechanistic Underpinnings of Pathology in Spinal Cord Injury and the Brain
Hudson, K. E., & Grau, J. W. (2022) · Cells · doi:10.3390/cells11182910 · Cited by 17
“In fact, over the course of a single year, nearly 13% of adults in the United States were prescribed benzodiazepines [14].”
BackgroundInfluentialEvidence of the emergence of illicit benzodiazepines from online drug forums
Sarker, A., Al-Garadi, M. A., Ge, Y., Nataraj, N., McGlone, L., Jones, C. M., & Sumner, S. A. (2022) · European Journal of Public Health · doi:10.1093/eurpub/ckac161 · Cited by 17
A Systematic Review of the Risks of Motor Vehicle Crashes Associated with Psychiatric Disorders
Rapoport, M. J., Chee, J. N., Prabha, T., Dow, J., Gillespie, I., Koppel, S., Charlton, J., O’Neill, D. J., Donaghy, P. C., Ho, A. O., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221128468 · Cited by 16
Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach
Pallanti, S., Zohar, J., Kasper, S. F., Möller, H., & Hollander, E. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.11.042 · Cited by 15
Benzodiazepine Use and Long-Term Mortality in South Korean Adult Population: A Cohort Study
Oh, T. K., Park, H. Y., & Song, I. (2021) · Yonsei Medical Journal · doi:10.3349/ymj.2021.62.6.528 · Cited by 16
Lorenzo, R. D., Perrone, D., Montorsi, A., Balducci, J., Rovesti, S., & Ferri, P. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s251993 · Cited by 15
Bushnell, G., Ivanenko, A., Horton, D. B., Lunsford‐Avery, J. R., Posner, J. E., Gerhard, T., Suarez, E. A., & Olfson, M. (2024) · SLEEP · doi:10.1093/sleep/zsae057 · Cited by 15
Niznik, J. D., Ferreri, S. P., Armistead, L. T., Urick, B. Y., Vest, M., Zhao, L., Hughes, T. D., McBride, J. M., & Busby‐Whitehead, J. (2022) · Trials · doi:10.1186/s13063-022-06164-5 · Cited by 13
“Opioids and BZDs are CNS-active medications that are challenging to appropriately prescribe and monitor, yet are commonly used in older adults [4, 5].”
BackgroundZanardi, R., Carminati, M., Fazio, V., Maccario, M., Verri, G., & Colombo, C. (2023) · Pharmaceuticals · doi:10.3390/ph16030426 · Cited by 18
“Due to their rapid effectiveness and low toxicity, BDZs often represent the first treatment administered by general practitioners and other specialists, also outside of psychiatric setting [6,7].”
BackgroundTejedor, A., Bravo, J. C., González, G. P., Martínez, R. M. G., & Hernando, P. F. (2024) · Polymers · doi:10.3390/polym16050635 · Cited by 13
“Over the past few years, the misuse and abuse of benzodiazepines (BZDs) has become a health issue [1,2].”
BackgroundBenzodiazepine and unhealthy alcohol use among adult outpatients.
Hirschtritt, M. E., Palzes, V. A., Kline‐Simon, A. H., Kroenke, K., Campbell, C. I., & Sterling, S. (2019) · PubMed · Cited by 23
Carminati, M., Tondello, M., & Zanardi, R. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1471083 · Cited by 13
“Nevertheless, due to their rapid effectiveness in reducing sleep disturbances and anxiety symptoms, BDZs are often the initial treatment prescribed by both general practitioners and other specialists (3, 4).”
BackgroundKang, H., Hunniecutt, J. R., Silva, L. Q., Kaskie, B. P., & Bobitt, J. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2021.1903479 · Cited by 14
“Older adults also are more likely than younger adults to use benzodiazepines more often than prescribed and to help them with sleep (15).”
BackgroundRepresentation of Benzodiazepines in Treatment Guidelines: The Paradox of Undesirable Objectivity
Starčević, V. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524772 · Cited by 12
Walking the Benzodiazepine High Wire
Kroenke, K., & Hirschtritt, M. E. (2022) · Psychiatric Services · doi:10.1176/appi.ps.202100671 · Cited by 12
Racial-Ethnic Disparities in Benzodiazepine Prescriptions for Anxiety in US Emergency Departments
Ribas Roca, J., Everett, T., Dongarwar, D., & Salihu, H. M. (2023) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-021-01224-z · Cited by 11
“6%) report use of benzodiazepines each year with adults aged 50–64 having the highest rates of prescription use [4].”
BackgroundInfluentialLynch, T., Ryan, C., Huff, C., Foster, D. E., & Cadogan, C. (2024) · Health Expectations · doi:10.1111/hex.13962 · Cited by 11
“2,3 6 For example, over 30 million adults (12.6% of the population) in the US reported BZRA use in the past year 6 and it has previously been estimated that long ‐ term use accounts for 30% – 40% of BZRA prescribing.”
BackgroundInfluentialMazzitelli, M., Trunfio, M., Coin, A., Sasset, L., Farina, J., Brundu, M., Scaglione, V., Devita, M., Sergi, G., & Cattelan, A. M. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad348 · Cited by 12
Maust, D. T., Takamine, L. H., Wiechers, I. R., Blow, F. C., Bohnert, A. S. B., Strominger, J., Min, L. C., & Krein, S. L. (2022) · The Annals of Family Medicine · doi:10.1370/afm.2825 · Cited by 12
Self-citationCeuterick, M., Ngoc, P. V., Bracke, P., & Scholtes, B. (2023) · Social Science & Medicine · doi:10.1016/j.socscimed.2023.116358 · Cited by 13
Wang, C., Wang, X., Wang, J., Li, X., Lu, D., Guo, F., Yao, Y., Zhu, J., Shen, C., Xie, Q., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.07.142 · Cited by 11
Lomachinsky, V., Brooks, J. D., Donahue, M. A., Sun, S., Hsu, J., Price, M., Blacker, D., Schwamm, L. H., Newhouse, J. P., Haneuse, S., et al. (2024) · Stroke · doi:10.1161/strokeaha.124.047257 · Cited by 11
Richardson, J. K., Eckner, J. T., Kim, H., & Ashton‐Miller, J. A. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120915409 · Cited by 11
“About 30 million adults receive benzodiazepine prescriptions annually in the United States (Maust et al., 2019).”
BackgroundChamplain, A. F. D., Ashworth, N. L., Kain, N. A., Qin, S., Wiebe, D., & Tian, F. (2020) · Journal of Medical Regulation · doi:10.30770/2572-1852-106.4.17 · Cited by 14
Cogan, J. C., Raghunathan, R. R., Beauchemin, M., Accordino, M. K., Elkin, E. B., Melamed, A., Wright, J. D., & Hershman, D. L. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06275-8 · Cited by 12
Metabolism and detection of designer benzodiazepines: a systematic review
Gameli, P. S., HUESTIS, M., Balloni, A., Busardò, F. P., & Carlier, J. (2024) · Drug Metabolism Reviews · doi:10.1080/03602532.2024.2410747 · Cited by 11
“…and illicit use of benzodiaze-pines globally led to stringent prescription regulations; however, the synthesis and/or re-discovery of new derivatives, and analogs classified as new psychoactive substances (NPS) further complicated their illicit use (Manchester et al. 2018; Maust et al. 2019).”
Matheson, C., Vucic, C., Dumbrell, J., Robertson, R., Ritchie, T., Duncan, C., Kessavalou, K., Woolston, C., & Schofield, J. (2024) · Pharmacy · doi:10.3390/pharmacy12050152 · Cited by 10
“This pattern of increased benzodiazepine use/misuse is also becoming evident in, for example, Northern Ireland [5] and the USA [6].”
Sinclair, J., Kalk, N. J., Kaar, S. J., Agabio, R., Arunogiri, S., Bisaga, A. M., Chesney, E., Daly, C., Dewhurst, J., Freeman, T. P., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251399593 · Cited by 16
“In the therapeutic use group, safe withdrawal with minimal side effects is key, as well as awareness of the potential re-emergence of any underlying conditions, and the increased mortality from all causes in people who discontinue benzodiazepine use after stable long-term use (Maust et al., 2018).”
Caballero‐Casero, N., Mihretu, L. D., & Rubio, S. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab023 · Cited by 10
Teixeira, A. L. D. S., Nardone, M., Samora, M., Fernandes, I. A., Ramos, P. S., Sabino‐Carvalho, J. L., Ricardo, D. R., Millar, P. J., & Vianna, L. C. (2022) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00291.2021 · Cited by 10
Designer Benzodiazepines: Effects, Toxicity, and Interactions
Balkhi, S. E., & Abbara, C. (2023) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001071 · Cited by 12
A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
He, W., Wang, Y., & Chen, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1278442 · Cited by 10
Simultaneous Benzodiazepine and SSRI Initiation in Young People With Anxiety Disorders
Bushnell, G., Rynn, M. A., Crystal, S., Gerhard, T., & Olfson, M. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13863 · Cited by 10
Bakavoly, M. E., Sajjadi, M., Ghasemi, R., & Ajamzibad, H. (2023) · Iranian Journal of Nursing and Midwifery Research · doi:10.4103/ijnmr.ijnmr_332_21 · Cited by 10
“Benzodiazepines are the most commonly used drugs to treat insomnia.[8] These drugs reduce the nervous system’s function in people, so they may endanger their safety.”
BackgroundUsages et bon usage des benzodiazépines anxiolytiques et hypnotiques
Bonnay, M., Soeiro, T., Mégard, R., Micallef, J., Rolland, B., & Chappuy, M. (2021) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2021.08.009 · Cited by 15
Thomas, C., Dondaine, T., Caron, C., Bastien, A., Chérot‐Kornobis, N., Deheul, S., Gautier, S., Cottencin, O., Moreau-Crépeaux, S., Bordet, R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-63037-4 · Cited by 13
“Similarly, Maust et al. found that in almost all cases, past-year use of tobacco, alcohol, cannabis, heroin, opioid drugs or prescription stimulants was associated with benzodiazepine use 24 .”
BackgroundWang, L., Wang, R., Zheng, Q., Yao, X., Zhang, C., Fu, S., Wei, Z., Yun, K., & Guo, Z. (2023) · NeuroToxicology · doi:10.1016/j.neuro.2023.01.012 · Cited by 10
Jovita-Farias, C., Follett, M. E., Dias-Júnior, B. C., Serra, Y. A., Kisaki, N. D., Barros-Santos, T., de Jesus, N. M. S., Rodrigues, I. R. S., Macedo, L. E. L., Malpezzi-Marinho, E. L. A., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1122568 · Cited by 9
Taha, S. A., Westra, J. R., Tacker, D. H., Raji, M. A., & Kuo, Y. (2023) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2023.102584 · Cited by 13
“(Maust et al., 2019) The South had the highest concurrent use rates, which may be due to the increased prevalence of severe mental illness, (Lipari et al., 2013) UDT rates, and the large market share of CDM data in the South, and potentially indicate a lack of alternative treatments to…”
BackgroundDrug Safety and Suicidality Risk of Chronic Pain Medications
Syed, O., Jancic, P., Fink, A. B., & Knežević, N. N. (2023) · Pharmaceuticals · doi:10.3390/ph16101497 · Cited by 12
Friestino, J. K. O., Luzardo, A. R., Gralak, É. Z., Gass, L. S., Guimarães, P. G. Z., & Barbato, P. R. (2020) · Salud Colectiva · doi:10.18294/sc.2020.2495 · Cited by 9
“A lo largo de los últimos 20 años, con el aumento del consumo de benzodiazepinas en Brasil y en el mundo, se realizaron diversos estudios sobre el tema(15) que caracterizan el uso de los fármacos(16,17), analizan las prescripciones(18) y evalúan la orientación médica respecto de los fármacos(19).”
BackgroundCerne, R., Smith, J. L., Chrzanowska, A., & LIPPA, A. S. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173895 · Cited by 9
Trager, R. J., Cupler, Z. A., Delano, K. J., Perez, J. A., & Dusek, J. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058769 · Cited by 9
Chen, C., Hennessy, S., Brensinger, C. M., Acton, E. K., Bilker, W. B., Chung, S. P., Dawwas, G. K., Horn, J. R., Miano, T. A., Nguyen, T. P. P., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19551-4 · Cited by 9
“Patients were followed from the first day of base pair use until: (1) discontinuation of the base pair, defined as ≥ 1 day without supply of either the BZD or co-dispensed drug; to permit late prescription fills consistent with imperfect adherence, we extended BZD and co-dispensed drug days’ supply values by 20%; (2)…”
MethodSedative-hypnotic Co-prescribing with Opioids in a Large Network of Community Health Centers
Hartung, D. M., Lucas, J., Huguet, N., Bailey, S. R., O'Malley, J. P., Voss, R., Chamine, I., & Muench, J. (2023) · Journal of Primary Care & Community Health · doi:10.1177/21501319221147378 · Cited by 8
Metadata
- Authors
- Maust, D. T., Lin, L. A., & Blow, F. C.
- Affiliations
- University of Michigan (US)
- Venue
- Psychiatric Services
- Published
- 2019-02-01
- Volume
- 70
- Issue
- 2
- Pages
- 97-106
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- PMC
- PMC6358464
- OpenAlex
- W2904755589
- Cited by
- 337
- References
- 42
- Citations by year
- 2026: 40 · 2025: 50 · 2024: 72 · 2023: 48 · 2022: 56 · 2021: 27 · 2020: 35 · 2019: 8
- FWCI
- 16.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Psychiatric Services (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R01DA045705)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- benzodiazepine misuse, benzodiazepine use, prescription drug misuse, prevalence, age differences, substance use disorders, opioid misuse, stimulant abuse, sleep aids, benzodiazepine dependence, National Survey on Drug Use and Health
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Benzodiazepines, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Drug Prescriptions, United States, Prevalence, Young Adult, Prescription Drug Misuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.